382 related articles for article (PubMed ID: 22736392)
1. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
[TBL] [Abstract][Full Text] [Related]
2. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer.
Jao SW; Chen SF; Lin YS; Chang YC; Lee TY; Wu CC; Jin JS; Nieh S
Ann Surg Oncol; 2012 Oct; 19(11):3432-40. PubMed ID: 22739652
[TBL] [Abstract][Full Text] [Related]
3. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Ioue Y; Miki C; Kusunoki M
Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699
[TBL] [Abstract][Full Text] [Related]
4. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer.
Wang Q; Chen ZG; Du CZ; Wang HW; Yan L; Gu J
Histopathology; 2009 Sep; 55(3):284-93. PubMed ID: 19723143
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of CD133 and hypoxia inducible factor-1α gene expression in rectal cancer after preoperative chemoradiotherapy.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Koike Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):323-32. PubMed ID: 20970309
[TBL] [Abstract][Full Text] [Related]
6. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer.
Yasuda H; Tanaka K; Saigusa S; Toiyama Y; Koike Y; Okugawa Y; Yokoe T; Kawamoto A; Inoue Y; Miki C; Kusunoki M
Oncol Rep; 2009 Oct; 22(4):709-17. PubMed ID: 19724847
[TBL] [Abstract][Full Text] [Related]
7. ALDH1 is a prognostic factor for patients treated with neoadjuvant chemoradiotherapy and radical resection for stage III rectal cancer.
Oh SY; Sohn SH; Yim H; Lee D; Suh KW; Kim YB
J Surg Oncol; 2015 Feb; 111(2):243-7. PubMed ID: 25270363
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment CD133 and cyclooxygenase-2 expression as the predictive markers of the pathological effect of chemoradiotherapy in rectal cancer patients.
Shinto E; Hashiguchi Y; Ueno H; Kobayashi H; Ishiguro M; Mochizuki H; Yamamoto J; Hase K
Dis Colon Rectum; 2011 Sep; 54(9):1098-106. PubMed ID: 21825889
[TBL] [Abstract][Full Text] [Related]
9. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis.
Hecht M; Büttner-Herold M; Erlenbach-Wünsch K; Haderlein M; Croner R; Grützmann R; Hartmann A; Fietkau R; Distel LV
Eur J Cancer; 2016 Sep; 65():52-60. PubMed ID: 27468145
[TBL] [Abstract][Full Text] [Related]
11. Increased CD133 expression after preoperative chemoradiotherapy in rectal cancers other than mucin-rich tumors.
Lin CH; Chen WT; Liu CH; Tsai HP; Wu CC; Chai CY
Virchows Arch; 2012 May; 460(5):447-53. PubMed ID: 22453233
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy.
García VM; Batlle JF; Casado E; Burgos E; de Castro J; Belda C; Barriuso J; Sánchez JJ; García-Cabezas MÁ; González-Barón M; Cejas P
Colorectal Dis; 2011 Sep; 13(9):989-98. PubMed ID: 20718834
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer.
Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Morimoto Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
Oncol Rep; 2010 Aug; 24(2):345-50. PubMed ID: 20596619
[TBL] [Abstract][Full Text] [Related]
14. Combination of growth pattern and tumor regression identifies a high-risk group in neoadjuvant treated rectal cancer patients.
Jessberger J; Erlenbach-Wünsch K; Posselt R; Haderlein M; Agaimy A; Fietkau R; Hartmann A; Distel L
J Dig Dis; 2017 May; 18(5):283-291. PubMed ID: 28342240
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment.
Lönnroth C; Andersson M; Nordgren S; Lundholm K
Int J Oncol; 2012 Jul; 41(1):15-23. PubMed ID: 22552364
[TBL] [Abstract][Full Text] [Related]
16. [Hypoxia-inducible factor-1α and CD133 predicts pathological complete response and survival for locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy].
Cai C; Wang J; Zhong Z; Dai Z; Wang Q; Dong W; Shi H; Liu Q; DU J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 46(1):36-43. PubMed ID: 28436629
[TBL] [Abstract][Full Text] [Related]
17. CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer.
Lee HH; Seo KJ; An CH; Kim JS; Jeon HM
J Surg Oncol; 2012 Dec; 106(8):999-1004. PubMed ID: 22674531
[TBL] [Abstract][Full Text] [Related]
18. CD133 expression in rectal cancer after preoperative chemoradiotherapy.
Kojima M; Ishii G; Atsumi N; Nishizawa Y; Saito N; Ochiai A
Cancer Sci; 2010 Apr; 101(4):906-12. PubMed ID: 20219069
[TBL] [Abstract][Full Text] [Related]
19. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
Song W; Li H; Tao K; Li R; Song Z; Zhao Q; Zhang F; Dou K
Int J Clin Pract; 2008 Aug; 62(8):1212-8. PubMed ID: 18479363
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
